Avigen Expands Board of Directors
February 06, 2007 15:52 ET
|
Avigen, Inc.
ALAMEDA, Calif., Feb. 6, 2007 (PRIME NEWSWIRE) -- Avigen, Inc. (Nasdaq:AVGN), a biopharmaceutical company developing innovative therapies for the treatment of neurological conditions, today announced...
Avigen Completes Safety, Tolerability and Pharmacokinetic Trial For AV411, a Potential First-in-Class Oral Treatment For Neuropathic Pain
February 06, 2007 08:00 ET
|
Avigen, Inc.
ALAMEDA, Calif., Feb. 6, 2007 (PRIME NEWSWIRE) -- Avigen, Inc. (Nasdaq:AVGN) today announced findings from a safety and tolerability study with AV411 (ibudilast), an oral therapy intended for the...
Avigen to Present At RBC Capital Markets Healthcare Conference
December 07, 2006 08:00 ET
|
Avigen, Inc.
ALAMEDA, Calif., Dec. 7, 2006 (PRIME NEWSWIRE) -- Avigen, Inc. (Nasdaq:AVGN), a biopharmaceutical company developing innovative therapies for the treatment of neurological conditions, announced today...
Avigen Completes Phase I Trial for AV650, an Oral Treatment for Neuromuscular Spasm and Spasticity
December 06, 2006 08:00 ET
|
Avigen, Inc.
ALAMEDA, Calif., Dec. 6, 2006 (PRIME NEWSWIRE) -- Avigen, Inc. (Nasdaq:AVGN) today announced findings from a Phase I clinical trial for AV650 (tolperisone), an oral therapy intended for the treatment...
Avigen to Present At Upcoming Healthcare Conferences
November 01, 2006 08:30 ET
|
Avigen, Inc.
ALAMEDA, Calif., Nov. 1, 2006 (PRIMEZONE) -- Avigen, Inc. (Nasdaq:AVGN), a biopharmaceutical company developing innovative therapies for the treatment of neurological conditions, announced today that...
Avigen Reports Third Quarter 2006 Financial Results
October 25, 2006 05:00 ET
|
Avigen, Inc.
ALAMEDA, Calif., Oct. 25, 2006 (PRIMEZONE) -- Avigen, Inc. (Nasdaq:AVGN) today reported financial results for the three and nine months ended September 30, 2006. At September 30, 2006, Avigen had...